Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CEFOTAXIME SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CEFOTAXIME SODIUM.
ARBLI vs CEFOTAXIME SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-1A and PBP-3, leading to cell lysis and death.
10 mg orally once daily.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Terminal elimination half-life is 0.9-1.5 hours in adults with normal renal function; prolonged to 2.5-10 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-6 hours.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal (50-60% unchanged), biliary (5-10%), with approximately 20-30% metabolized to desacetylcefotaxime (also renally eliminated). Total renal elimination of parent drug and metabolite accounts for >80%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic